Switzerland Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this interview, Nasri discusses Biopôle’s key priorities, including the integration of AI and data, sustainability in life sciences, and the importance…
Switzerland Oliver Kuhn, CEO of Selectchemie, has had a diverse career spanning various sectors, starting in the financial industry before transitioning to healthcare. Under his leadership, Selectchemie has sharpened its strong focus on high-quality APIs, excipients, as well as own dossiers and finished-dose-formulations, setting itself apart through a tailored service that…
Puerto Rico We’re not just reconnecting with our roots—we’re planting new ones. The PDA Puerto Rico chapter is a bridge between our island’s rich pharmaceutical legacy and a future powered by innovation, collaboration, and purpose. The Parenteral Drug Association (PDA) is a non-profit global organisation established in 1946, providing support to the…
Germany After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve as the framework for the new German government’s healthcare agenda . While the accord presents broad healthcare reforms, the key…
Puerto Rico We’re not just building facilities—we’re building the future of medicine, where innovation is inclusive, access is equitable, and every breakthrough brings us closer to a healthier world. Biopharmaceutical innovation is advancing rapidly, yet inefficiencies in development and manufacturing continue to slow progress. OcyonBio, under the leadership of CEO Robert Salcedo,…
Saudi Arabia As Saudi Arabia continues its ambitious healthcare transformation under Vision 2030, the Ministry of Health is playing a central role in reimagining the nation’s approach to health and wellness. Fahad bin Abdulrahman AlJalajel, His Excellency, the Minister of Health, outlines key milestones in the shift toward a value-based healthcare system,…
Global Paola Barbarino, CEO of Alzheimer’s Disease International, shares her insights into the growing global challenge of the disease and the urgent need for action across all income settings. In this interview, she discusses the importance of post-diagnosis support, the burden on caregivers, the impact of stigma, and the role of governments…
Australia Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the 2025 Australian federal election, which will be held on Saturday, 3 May, just 5 days after Canada’s forthcoming national election.…
Brazil After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the Japanese drugmaker, Rodriguez will be taking on a country full of opportunities and challenges. With more dengue cases than anywhere…
Global Writing in the April 2025 edition of DIA’s Global Forum magazine, Christopher Morrison and Richard Xie of RA Capital Management L.P., introduce the recently published cost-effectiveness analyses methodology which incorporates key value elements and drivers that are omitted or incompletely captured in traditional clinical outcome assessments. Accelerating scientific discoveries…
Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…
USA While on the surface it may look like pharmaceuticals have been spared by Donald Trump’s “Liberation Day” trade policies, drugmakers still lack a clear picture of how they will be impacted. The US president has not, as of yet, imposed “25 percent or higher” tariffs as originally pledged, but that…
See our Cookie Privacy Policy Here
